<div class="xbrl-content"> <h3>Quarterly report pursuant to Section 13 or 15(d)</h3> <div id="xbrl-menu-top"> <div class="navigation"> <ul class="xbrl-sf-menu"> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3082">Cover</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3082">Document And Entity Information</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3083">Financial Statements</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3083">CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3084">CONDENSED CONSOLIDATED BALANCE SHEETS</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3085">CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3086">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</a></li> </ul> </li> <li> <a class="menu-item current" href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3087">Notes to Financial Statements</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3087">Basis of Presentation and Summary of Significant Accounting Policies</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3088">Revenue Recognition</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3089">Selected Balance Sheet Data</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3090">Acquisitions</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3091">Fair Value Measurements</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3092">Debt and Other Financing Arrangements</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3093">Leases</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3094">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3095">Earnings Per Share</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3096">Share-based Compensation</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3097">Other Income / (Expense)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3098">Income Taxes</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3099">Segment Information</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3100">Subsequent Events</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3101">Pay vs Performance Disclosure</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3102">Insider Trading Arrangements</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3103">Accounting Policies</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3103">Basis of Presentation and Summary of Significant Accounting Policies (Policies)</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3104">Notes Tables</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3104">Basis of Presentation and Summary of Significant Accounting Policies (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3105">Revenue Recognition (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3106">Selected Balance Sheet Data (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3107">Acquisitions (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3108">Fair Value Measurements (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3109">Leases (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3110">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3111">Earnings Per Share (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3112">Other Income / (Expense) (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3113">Segment Information (Tables)</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3114">Notes Details</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3114">Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3115">Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3116">Revenue Recognition - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3117">Revenue Recognition - Disaggregation of Revenue (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3118">Selected Balance Sheet Data - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3119">Selected Balance Sheet Data - Inventories (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3120">Selected Balance Sheet Data - Property and Equipment (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3121">Selected Balance Sheet Data - Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3122">Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3123">Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3124">Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3125">Selected Balance Sheet Data - Other Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3126">Acquisitions - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3127">Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3128">Fair Value Measurements - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3129">Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3130">Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3131">Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3132">Debt and Other Financing Arrangements - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3133">Leases - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3134">Leases - Balance Sheet Classification (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3135">Leases - Cash Paid (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3136">Leases - Fair Value of the Lease Liability by Payment Date (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3137">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3138">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3139">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3140">Earnings Per Share - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3141">Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3142">Share-based Compensation (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3143">Other Income / (Expense) - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3144">Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3145">Income Taxes (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3146">Segment Information - Financial Information Relating to Reportable Segments (Details)</a></li> </ul> </li> </ul> </div> </div> <div class="spr-xbrl-document"> <h4>Acquisitions</h4> <title></title> <span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45979235993152"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Sep. 30, 2024</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td> <td class="text"> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Note 4. Acquisitions:</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our consolidated statements of comprehensive income from their respective dates of acquisitions. Acquisition costs are recorded in Selling, general and administrative expenses as incurred.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no acquisitions in the first quarter of fiscal 2025. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fiscal year 2024 Acquisitions</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Lunaphore Technologies SA.</i></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On July 7, 2023, the Company acquired all of the ownership interests of Lunaphore Technologies SA (“Lunaphore”) for </span><span style="background:#ffffff;">$169.7</span><span style="background:#ffffff;"> million, in a cash-free, debt-free acquisition. Lunaphore is a leading developer of fully automated spatial biology solutions. The Lunaphore acquisition adds spatial biology instruments to Bio-Techne’s portfolio to accelerate our leadership position in translational and clinical research markets. </span>The transaction was accounted for in accordance with ASC <i style="font-style:italic;">805,</i> <i style="font-style:italic;">Business Combinations</i>. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Spatial Biology operating segment in the first<i style="font-style:italic;"> </i>quarter of fiscal year 2024.<i style="font-style:italic;"> </i></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">The allocation of purchase price consideration related to Lunaphore was completed in the fourth quarter of fiscal 2024. The fair values of the assets acquired and liabilities assumed as of June 30, 2024 are as follows (in thousands):</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"> <tr style="height:1pt;"> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td colspan="2" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Final allocation at June 30, 2024</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,155</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment and other long-term assets</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,470</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets:</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Developed technologies</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,300</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Tradenames</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,900</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Customer relationships</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,650</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total assets acquired</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,675</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,096</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income taxes, net</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,872</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net assets acquired</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,707</p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td> </tr> <tr> <td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td> <td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,707</p></td> </tr> </table> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology and customer relationships was based on management’s forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The purchase price allocated to trade names was based on management's forecasted cash inflows and outflows and using a relief from royalty method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is 8 years. The amount recorded for trade names is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names ranges from 4 years to 8 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the calculation of acquired net operating losses.</p> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> <div style="clear:both;"></div> </div> </div> <link rel="stylesheet" href="//investors.bio-techne.com/stylesheets/xbrl.css" type="text/css">